US FDA orders opioid makers to develop doctor education programmes
This article was originally published in SRA
Executive Summary
In an effort to tackle the epidemic of abuse and misuse of prescription opioid painkillers in the US, officials from the Food and Drug Administration, the Drug Enforcement Administration, the Departments of Veterans Affairs and Defense and the White House Office of National Drug Control Policy have laid out a multi-prong strategy which includes the details of a much-anticipated risk evaluation and mitigation strategy (REMS) requirement for makers of all extended-release and long-acting opioid medications1.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: